Can chemo stop immunotherapy from backfiring in lung cancer?
NCT ID NCT07274384
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 21 times
Summary
This study is for people with advanced non-small cell lung cancer that has high PD-L1 levels. Some patients experience rapid tumor growth when treated with immunotherapy alone. The trial will test whether adding chemotherapy to the immunotherapy drug cemiplimab can prevent this dangerous reaction and improve survival. About 74 participants will be randomly assigned to receive either immunotherapy alone or immunotherapy plus chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.